Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.International Journal of Radiation Oncology, Biology, Physics|February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 TrialSarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.The Lancet. Oncology|September 4, 2025
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trialTamim Niazi, Fred Saad, Steven Tisseverasinghe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillanceChristian Kollmannsberger, Torgrim Tandstad, Philippe L Bedard, et al.BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Pan-Canadian consensus recommendations for proton beam therapy access in CanadaGunita Mitera, Derek Tsang, Boyd McCurdy, et al.European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapyJonas Willmann, Sarah Baker, Hanbo Chen, et al.JAMA Oncology|September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical TrialRobert Olson, Will Jiang, Mitchell Liu, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trialReno Eufemon Cereno, Benjamin Mou, Sarah Baker, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastasesRobert Olson, Mitchell Liu, Alanah Bergman, et al.Pageof 14